Literature DB >> 7523434

Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin.

M Toyoda1, X Zhang, A Petrosian, O A Galera, S J Wang, S C Jordan.   

Abstract

Intravenous immunoglobulin (IVIG) has the potential to regulate Ig production, but the mechanism(s) responsible for this effect is unknown. In experiments reported here, we examined the ability of IVIG to regulate Ig production in human peripheral blood mononuclear cells (PBMCs) stimulated with pokeweed mitogen (PWM). IVIG (2-10 mg/ml) showed a potent (80-85%) inhibition of PWM-stimulated IgG, IgM, and IgA production. To determine more precisely how IVIG mediated the inhibition of Ig production, we studied Ig promoting cytokine gene expression after PWM stimulation with or without IVIG (2 and 10 mg/ml) using dot-blot techniques. RNA was isolated from PBMCs at predetermined time points and probed with cDNAs specific for human cytokines (IL-1 beta, IL-2, IL-2R, IL-4, IL-5, IL-6, gamma-IFN, and TNF-alpha). IL-6 mRNA accumulation was maximal at 4.5 hr post-PWM stimulation and was inhibited 64-75% when IVIG (10 mg/ml) was present. gamma-IFN mRNA levels peaked at 72 hr poststimulation and were also 68-75% inhibited by IVIG. IL-2 mRNA levels peaked at 4.5 hr and were 23-46% inhibited by IVIG. The inhibitory effect of IVIG on production of these cytokines (IL-6 and gamma-IFN) was also observed at the protein level in sonicated PBMCs after incubation with PWM and IVIG. The mRNA levels for other cytokines were not or only minimally inhibited by IVIG. Addition of IL-6, gamma-IFN, or IL-2 partially restored Ig production in IVIG-treated PWM-stimulated cultures, suggesting that inhibition of other cytokines or another mechanism(s) independent of cytokine inhibition might also be involved, although inhibition of IL-6, gamma-IFN, and IL-2 may be one of the critical factors in the suppression of Ig production by IVIG.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523434     DOI: 10.1007/bf01533367

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  50 in total

1.  Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity.

Authors:  R I Schiff
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

2.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

3.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

4.  The T cell dependence of B cell differentiation induced by pokeweed mitogen.

Authors:  R G Keightley; M D Cooper; A R Lawton
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

5.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Human B cell differentiation. II. Suppression by T cells of T-dependent and T-independent plasma cell maturation.

Authors:  L T Bich-Thuy; J Brochier
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

7.  The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.

Authors:  S Mankarious; M Lee; S Fischer; K H Pyun; H D Ochs; V A Oxelius; R J Wedgwood
Journal:  J Lab Clin Med       Date:  1988-11

8.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

9.  Separable helper factors support B cell proliferation and maturation to Ig secretion.

Authors:  D C Parker
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

10.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

View more
  13 in total

Review 1.  Intravenous immunoglobulin and multiple sclerosis.

Authors:  Anat Achiron; Shmuel Miron
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  Cytokine gene expression in normal human lymphocytes in response to stimulation.

Authors:  J Fan; P Nishanian; E C Breen; M McDonald; J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

3.  Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?

Authors:  L Padet; I St-Amour; É Aubin; R Bazin
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

4.  Detection of autoantibodies to cytokines.

Authors:  K Bendtzen; M B Hansen; C Ross; M Svenson
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

5.  Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study.

Authors:  A Achiron; Z Rotstein; S Noy; S Mashiach; M Dulitzky; R Achiron
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

6.  Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates.

Authors:  K S Sivasai; T Mohanakumar; D Phelan; S Martin; M E Anstey; D C Brennan
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

7.  In vitro synthesis of human IgE is suppressed by human IgG.

Authors:  H Haas; M Schlaak
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

8.  Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients.

Authors:  K Ohkuma; T Sasaki; S Kamei; S Okuda; H Nakano; T Hamamoto; K Fujihara; I Nakashima; T Misu; Y Itoyama
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

9.  Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient.

Authors:  Ashim Aggarwal; Joseph Pyle; John Hamilton; Geetha Bhat
Journal:  Tex Heart Inst J       Date:  2012

10.  Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.

Authors:  Lakshman Puli; Yuriy Pomeshchik; Katja Olas; Tarja Malm; Jari Koistinaho; Heikki Tanila
Journal:  J Neuroinflammation       Date:  2012-05-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.